López L, Corte CLA, Navarrete FG

Idioma: Español
Referencias bibliográficas: 18
Paginas: 96-98
Archivo PDF: 146. Kb.

RESUMEN

El sarcoma de Kaposi es una neoplasia, habitualmente se presenta en miembros inferiores de varones de más de 60 años de edad, pero en las 2 últimas décadas se ha presentado en pacientes jóvenes portadores de VIH, con afección no sólo cutánea sino también de mucosas y vísceras. Presentamos un paciente masculino de 44 años con sarcoma de Kaposi endémico y VIH positivo.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Jones J, Hanson D, Dworkin M et al. Incidence and trends in Kaposi’s sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 24: 270-274.

2. Martin J, Ganem D, Osmond D et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338: 948–954.

3. Ziegler J, Templeton A, Vogel C. Kaposi’s sarcoma a comparison of classical, endemic, and epidemic forms. Semin Oncol 1984;11:47-52.

4. Krown S, Testa M, Huang J. AIDS related Kaposi’s sarcoma: prospective validation of the AIDS Clinical Group Oncology Committee. J Clin Oncol 1997; 15: 3085-3092.

5. Chang Y, Cesarman E, Pessin M et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994; 266: 1865-1869.

6. Mantina H, Kankasa C, Klaskala W et al. Vertical transmission of Kaposi’s sarcoma-associated herpes virus. Int J Cancer 2001; 94: 749-752.

7. Jacobson L, Jenkins F, Springer G et al. Interaction of human immunodeficiency virus type 1 and human herpes virus type 8 infections on the incidence of Kaposi’s sarcoma. J Infect Disease 2000; 181: 1940-1949.

8. Rezza G, Andreoni M, Dorrucci M et al. Human herpes virus 8 seropositivity and risk of Kaposi’s sarcoma and other acquired immunodeficiency syndrome-related diseases. J Nat Cancer Inst 1999; 91: 1468-1474.

9. Schwartz RA, Spicer MS, Janniger CK et al. Initial lesions of HIV-KS Keloidal Kaposi’s sarcoma: report of three patients. Dermatology 1994; 189: 271–274.

10. Franceschi S, Dal Maso L, Arniani S, Crosignani P, Vercelli M, Simonato L et al. Risk of cancer other than Kaposi’s sarcoma and non-Hodgkin’s lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer 1998; 78: 966-970.

11. Mocroft A, Kirk O, Clumeck N et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA study. Cancer 2004; 100: 2644–2654.

12. Franceschi S, Dal Maso L, Arniani S, Crosignani P, Vercelli M, Simonato L et al. Risk of cancer other than Kaposi’s sarcoma and non-Hodgkin’s lymphoma in persons with AIDS in Italy. Br J Cancer 1998; 78: 966-970.

13. Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS associated Kaposi’s sarcoma in the era of highly active antiretroviral therapy. Lancet 2006; 367: 1495-1502.

14. Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi’s. AIDS 1998; 12: 46-49.

15. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M et al. A comparison of regimens based on non nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi’s sarcoma. AIDS 2003; 17: 17-22.

16. Martínez V, Caumes E, Gambotti L, Ittah H, Morini J-P, Deleuze J, Gorin I, Katlama C, Bricaire F, Dupin N. Remission from Kaposi’s sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Brit J Cancer 2006; 94: 1000-1006.

17. Dezube BJ, Von Roenn JH, Wiltse J et al. Fumagillin analog in the treatment of Kaposi’s sarcoma a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998; 16: 1444-1449.

18. Koon HB, Bubley GJ, Pantanowitz et al. Imatinib induced regression of AIDS related Kaposi’s sarcoma. J Clin Oncol 2005; 23: 982-989.